PDT Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

PDT Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-59,552	Closed	-$831K	–	951
2022 Q3	$831K	Sell	59,552 -78,044	-57%	-$1.26M	0.13%	274
2022 Q2	$1.9M	Buy	137,596 +3,414	+3%	+$54.7K	0.17%	186
2022 Q1	$2.18M	Buy	134,182 +109,525	+444%	+$1.72M	0.19%	152
2021 Q4	$402K	Buy	+24,657	New	+$416K	0.03%	594
2021 Q3	–	Sell	-114,515	Closed	-$2.29M	–	950
2021 Q2	$2.29M	Buy	114,515 +3,923	+4%	+$77.8K	0.15%	253
2021 Q1	$2.55M	Buy	110,592 +5,988	+6%	+$167K	0.18%	232
2020 Q4	$2.58M	Sell	104,604 -242	-0.2%	-$8.02K	0.17%	222
2020 Q3	$4.35M	Buy	+104,846	New	+$4.82M	0.29%	146
2018 Q4	–	Sell	-53,932	Closed	-$6.82M	–	526
2018 Q3	$6.82M	Buy	53,932 +26,260	+95%	+$2.78M	0.28%	127
2018 Q2	$2.32M	Buy	+27,672	New	+$2.03M	0.09%	242
2014 Q4	–	Sell	-23,011	Closed	-$5.45M	–	1172
2014 Q3	$5.45M	Buy	+23,011	New	+$5.87M	0.14%	186

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PDT Partners's ICPT Position: Q4 2022 in Review

PDT Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 59,552 shares — an estimated $831K sold.

PDT Partners first reported a position in ICPT in Q3 2014 and held it in 11 quarters. The position peaked at $6.82M in Q3 2018. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

PDT Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
PDT Partners sold 59,552 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $831K.
PDT Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
PDT Partners's Intercept Pharmaceuticals, Inc. position peaked at $6.82M in Q3 2018.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.